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ABSTRACT

Despite continuous effort and progress in cancer detection and therapy, cancer
remains one of our greatest health concerns because of its low survival rate and rapid
incidence increase. One reason for this is the late detection and therefore pre-cancer
diagnosis is crucial. In pre-cancer studies, cancer biomarkers become significant because
of the useful information it contains such as possible cancer type and stage. Separation
and detection technique plays an important role in cancer biomarker identification.
Coenzyme A (CoA) facilitates more than 100 chemical reactions in cells. Because
of its low abundance accumulated in cells, it is critical to develop a sensitive method to
detect CoA compounds in biological samples in order to study it as a cofactor.
The valuable characteristics of capillary electrophoresis (CE), such as rapid
analysis, high separation efficiency and minimal consumption of sample and buffer
solutions, make it a unique analytical technique. The combination of the high specificity
and sensitivity of tandem mass spectrometry (MS/MS) with the high separation ability of
high performance liquid chromatography (HPLC) facilitates the sensitive and specific
analysis in complex matrices like urine and blood. In this body of work, new methods
were developed using CE-UV, CE-LIF and HPLC-MS/MS to determine modified
nucleosides, CoAs, and sarcosine, proline, kynurenine, uracil and glycerol-3-phosphate.
These methods were applied to measure the above mentioned analytes in either urine
samples or cell extracts and proved to be simple, fast, reliable and powerful. Based on
these newly developed methods, cancer biomarker screening is undertaken and new
biomarkers will be identified.
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1. INTRODUCTION

1.1. EARLY CANCER DETECTION

Cancer is a term used for diseases in which abnormal cells divide without control
and are able to invade other tissues. Cancer cells can spread to other parts of the body
through the blood and lymph systems and put high risk for human life. Figure 1.1
illustrates what happens when normal cells become cancer cells1. The body is made up of
many types of cells. These cells grow and divide in a controlled way to produce more
cells as they are needed to keep the body healthy. When cells become old or damaged,
they die and are replaced with new cells. However, sometimes this orderly process goes
wrong. The genetic material (DNA) of a cell can become damaged or changed, producing
mutations that affect normal cell growth and division. When this happens, cells do not die
when they should and new cells form when the body does not need them. The extra cells
may form a mass of tissue called tumor and malignant tumor is cancer. Cancer is a
serious health problem because cancer cells can spread to distant parts of the body. For
example, a melanoma (a cancer of pigmented cells) arising in the skin can have cells that
enter the bloodstream and spread to distant organs such as the liver or brain1. Melanoma
cells growing in the brain or liver can disrupt the functions of these vital organs and so is
potentially life threatening.
Despite continuous effort and progress in cancer detection and therapy, cancer
remains a significant health problem with a very low 5-year survival rate and a rapid
increase in its incidence. For example, there are around 11 million new cancer cases and
about 397,700 cancer-related deaths reported in United States in 20091, 2. Cancer is the
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second leading cause of death in USA. One reason for the high incidence and low
survival is the easier and more frequent exposure to carcinogens (cancer-causing agents)
which is responsible for triggering most human cancers. Although scientists don't know
all the reasons yet, many of the causes of cancer have already been identified. Besides
intrinsic factors such as heredity, diet, and hormones, scientific studies point to key
extrinsic factors that contribute to the cancer's development: chemicals (e.g., smoking,
alcohol, and industry pollution), radiation, and viruses or bacteria. Failing to take
appropriate steps to avoid these agents increases the cancer risk. Another reason for the
poor survival is that many cancers are detected late, often after they have metastasized to
distant sites. Once a cancer has spread, it is more difficult to eradicate. For many cancers,
there is no any symptom at its early stage. Patients visit the doctor only when they feel
pain or when they notice changes such as a lump in the breast or unusual bleeding or
discharge. Sometimes with these very apparent symptoms, the cancer is already in its late
stage and survival rate is very low. Therefore, early cancer screening even though
without any symptom is crucial.
For many cases, successful prevention depends on the accurate evaluation of risk,
and successful treatment depends on early detection. For example, the 5-year survival for
colorectal cancer is greater than 90% if it is detected while it is still localized, 30-50% if
detected with local lymph node involvement and only 10% if it has metastasized to
distant sites1. Finding cancer early may decrease a person's risk of dying from the cancer.
Consequently, many oncologists and cancer biologists are working to develop methods
that detect cancers at their early stages of development. Developing and improving
methods for early cancer detection is currently a high priority for cancer researchers.
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Figure 1.1. Illustrations of normal cells becoming to cancer cells1

1.2. BIOMARKERS

For many decades, the microscopy of biopsied samples has continued to be the
mainstay of definitive cancer diagnostic technique. However, this technique suffers from
intra-observational subjectivity. Also, detection of many cancers at the microscopic level
is often too late for successful intervention. Therefore, despite numerous technical
innovations in the quality of microscopic imagery, we are still limited in our ability to
detect cancer in their earliest stage of formation. After decades of basic research in
attempting to unravel the underlying cellular and molecular mechanisms of cancer, the
scientific community has uncovered novel candidate targets for the early cancer
detection. By the time a tumor is detected, several biological changes have already
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occurred. By reading these changes accurately, early detection and diagnosis of
individual cancers can be improved. Therefore, diagnostic assays to detect the changes
using biomarkers have considerable potential for early detection.
Normally, biomarkers are defined as cellular, biochemical and molecular
alterations by which normal, abnormal or simply biological processes can be recognized
or monitored. These alterations should objectively measure and evaluate normal
biological process, pathogenic processes, or pharmacologic responses to a therapeutic
intervention. In cancer research and detection, a biomarker refers to a substance or
process that is indicative of the presence of cancer in the body. It may be a molecule
secreted by a malignancy itself, or it can be a specific response of the body to the
presence of cancer3. Gene mutations, alterations in gene transcription and translation, and
alterations in their protein products can all potentially serve as specific biomarkers for
disease4, 5. The characteristics of an ideal biomarker have been described as follows6: (i)
specific for the malignant process; (ii) tumor type specific; (iii) readily detectable in body
fluids and tissue extracts; (iv) detectable early in the course of disease before the disease
is clinically evident; (v) indicative of the overall tumor cell burden; (vi) indicative of the
presence of micrometastases; and (vii) predictive of relapse. Biomarkers serve as
hallmarks for the physiological status of a cell at a given time and change during the
disease process. They are important tools for cancer detection and monitoring.
Cancer biomarker discovery has been and continues to be an active and
productive area of research and its practitioners are using ever-more sophisticated and
innovative technologies. Methods used for discovery frequently cast a wide net to allow
for the identification of new biomarkers. In the discovery phase, investigators typically
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identify genetic mutations in cancerous cells or compare gene or protein expression levels
in cancer and normal tissues to identify biomarkers that are either elevated or depressed
in cancerous tissues. Alternatively, differences in biological samples such as cell extracts,
sera, urine or sputum from control and cancer patients are investigated 3.

1.3. URINE SAMPLES
―There is perhaps no excretion of the human body which possesses more interest
to the medical practitioner, and probably none which throws so strong a light on the
organic processes of the diseased as well as the healthy body, as the urine.‖ 7
Examination of urine to determine a patient‘s health status has a long history,
being recorded as first practiced in 4000 B.C. by Sumerian and Babylonian physicians8.
Ancient clinicians detected glucose in the urine by tasting it or observing whether it
attracted ants. The presence of albumin in the urine has been measured as an indicator of
renal disease for centuries and in early times could be detected via the so-called ―foam
test‖ to determine whether albumin was present in the urine in large amounts. In the
modern clinical laboratory, routine urinalysis is frequently used to observe the status of a
patient‘s kidney function, bacterial infection, glucose levels, and for a variety of other
diagnostic reasons9. Moreover, urine sample collecting is relatively cheap, easy and
requires minimal amount of training. Unlike blood and tissue collecting, urine collecting
is also noninvasive, which is important sometimes. But, it still gives vital objective
information about the patients internal functioning. Although there is room to dispute
whether urine, blood, cerebrospinal fluid, or another bodily fluid has the greatest value in
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the diagnosis of diseases, there is no doubt that urine is an important biological matrix for
the determination of a patient‘s physical state10.
With the aid of modern analytical instrumentation and a solid foundation in
biochemistry, interest in the components of human urine as disease biomarker has greatly
expanded. Recently, more and more studies have been reported in the area of
determination and screening of cancer biomarkers using compounds in urine sample,
including nucleosides, ribonucleic acid (RNA), 8-hydroxydeoxyguanosine, DNA
mutation, DNA-adduct, glycans, proteins, glycoproteins, and small biomolecules11. The
latest developments and advances were focused on instrumental, methodical and data
analysis of different cancer biomarkers.

1.4. TECHNIQUES USED TO DETECT CANCER BIOMARKERS

Many different methods have been developed for screening cancer biomarkers
from saliva, sputum, serum, urine and tissues, such as high-performance liquid
chromatography- mass spectrometry (HPLC-MS) and gas chromatography- mass
spectrometry (GC-MS)12, 13, matrix assisted laser desorption ionization-mass
spectrometry (MALDI-MS)14-16, two-dimensional polyacrylamide gel electrophoresis (2D PAGE)17-21, surface-enhanced laser desorption ionization time of flight-mass
spectrometry (SELDI-TOF-MS)22-24, and so on. These sensitive techniques have been
extensively used to identify disease biomarkers in human biofluid, and great amount of
information has been obtained. For example, Petricoin et al.25 have used the proteomic
patterns in serum samples from the SELDI-MS spectrum to identify ovarian cancers.
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After studying of 50 ovarian cancer cases and 66 nonmalignant cases, their study results
yielded a sensitivity of 100%, specificity of 95%, and positive predictive value of 94%.
This technique could be effectively used for early-stage ovarian cancer screening. The
applications of SELDI-TOF- MS for diagnostic proteomics have been recently reviewed
by Issaq et al.23. This review has briefly covered the fundamental principles of SELDITOF-MS, sample preparation, protein identifications, diagnostic applications for diseases
including cancers, and other biological applications.
Capillary electrophoresis (CE) is a highly efficient analytical technique that has
had a great impact in biomedical research and clinical and forensic practices in the last
decade26-28. CE has been coupled to different detection methods based on the nature of
analytes29, including ultraviolet-visible (UV) absorption, conductimetry, MS, patch
clamp, electrochemical (EC) detection, and laser-induced fluorescence (LIF). With these
versatile methods of detection, CE has been quite capable in studying a variety of
analytes from smaller molecules (inorganic ions and organic molecules) to larger
biomolecules (DNA and proteins). Compared to other sensitive analytical techniques
such as HPLC and GC, which have been extensively used for analysis of biologically
active substances in clinical routines, CE holds a number of distinct advantages: (i) A
very small sample volume is needed for a single run (nL), which makes CE an ideal
analytical technique for applications that require analysis of low nanoliter samples and
subfemtomole quantities. Researchers have downscaled the sample volume for CE
analysis to less than picoliters, but the mass detection limits remain in the zeptomole
range30, 31. Recently, CE has been reportedly used in single cell analysis32, 33 and even
subcellular-level analysis34. (ii) CE‘s waste is safer for the environment than that from
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HPLC, which produces large amounts of organic waste, or than that from GC, which
produces volatile air pollutants27. Other advantages are rapid analysis, great resolution,
low cost, etc. All of these advantages designate CE as almost ideal for the analysis of
numerous endogenous and exogenous substances present in biological fluids35, 36.
During the past ten years, high performance liquid chromatography- mass
spectrometry-mass spectrometry (HPLC-MS/MS) has become one of the fastest growing
analytical techniques for the determination of trace level compounds. This technique
involves using two mass spectrometers, in tandem, as the detector for an HPLC. The ion
fragments from the first mass spectrometer (parent ions) are accelerated into the second
mass spectrometer, where secondary ionization occurs (daughter ions). This results in a
highly sensitive and highly selective detection. Tandem mass combined with the
separation power of HPLC minimizes interferences in the complex matrix and has
revolutionized the way we do chemical analysis today. HPLC-MS/MS offers a revolution
in the ability to identify compounds which are undetectable by other technologies. HPLC
coupled with tandem mass has been applied in a wide range of research areas, including
food safety, environmental protection, and pharmaceutical development.

1.5. THIS DISSERTATION

Different biomarkers have different functions in biological systems, but they each
have their own special characteristics. Monitoring the concentrations of biomarkers in
urine or cell extract is the easiest way to observe the clinical significance of a cancer
patient‘s status at regular intervals, and still be capable of predicting tumor formation and
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relapse. In this dissertation, modified nucleosides, sarcosine and related metabolites were
in urine samples were studied as the potential cancer biomarkers.
Nucleosides are primary constituents of ribonucleic acids (RNAs). When RNAs
are biotransformed, the normal nucleosides can either be metabolized or reutilized to
synthesize nucleic acid. However, in particular cases, some RNAs are transformed into
modified nucleosides which can neither be further degraded nor reutilized, but are
excreted intact in urine as end products due to a lack of specific phosphorylases 37. In
cancer disease where cell proliferation takes place, RNA metabolism increases
dramatically and higher concentrations of excreted modified nucleosides will be
observed. Consequently, the levels of modified nucleosides in urine can reflect RNA
degradation in the organism and so they can be used as potential cancer biomarkers. One
example of the possible pathway from normal nucleoside (A) to modified nucleosides
(m1A, I, m6 A, m1I, m6, 6 A) is shown in Figure 1.238.
Mapping the differential metabolomic profiles to their respective biochemical
pathways as outlined in the Kyoto Encyclopedia of Genes and Genomes (KEGG, release
41.1, http://www.genome.jp/kegg) revealed an increase in amino acid metabolism and
nitrogen breakdown pathways during cancer progression to metastatic disease. A similar
enrichment network of amino acid metabolism was also identified by the bioinformatics
tool Oncomine Concept Map4, 5(OCM, http://www.oncomine.org, P56310213), which is
shown in Figure 1.339. Additionally,OCM found strong enrichment for increased
‗methyltransferase activity‘ among metabolites upregulated in metastatic samples.
Because amino acid metabolism and methylation were enriched during prostate cancer
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progression, we focused on five metabolites (sarcosine, proline, kynurine, uracil and
glycerol-3-phosphate) as potential cancer biomarkers.

Figure 1.2. Illustration of possible pathways from normal nucleosides to modified
nucleosides38

For the determination of different biomarkers, CE and HPLC-MS/MS will be a
highly efficient analytical technique with great potential in biomarker researches due to
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their high qualities mentioned above. Because these techniques‘ history is relatively short
compared to many other analytical techniques, much work needs to be done to make CE
and HPLC-MS/MS be widely used in routine tests in various clinic laboratories. In this
dissertation, new methods were developed based on modified nucleosides, sarcosine and
related metabolites as cancer biomarkers using CE-UV/LIF and HPLC-MS/MS. These
methods were proved to be simple, fast, reliable and powerful. They are very crucial in
cancer biomarker identification and confirmation. Through large amount of biological
samples analysis using these newly developed assays, new biomarkers can be identified
and confirmed and more lives will be saved.

Figure 1.3. Oncomine concept analysis of metabolomic profiles of prostate cancer
progression39. Network view of the molecular concept analysis for the metabolomic
profiles of ―over-expressed in PCA signature‖ (blue node). Each node represents a
molecular concept or a set of biologically related genes. The node size is proportional to
the number of genes in the concept. Each edge represents a statistically significant
enrichment (P < 1 X 10-4). (Enrichments with interconnected‗amino acid metabolism
concepts‘, indicating increased amino acid metabolism in PCA versus benign, are
indicated by red edges.
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PAPER

1. A Fast Capillary Electrophoresis Method for Separation and Quantification
of Modified Nucleosides in Urinary Samples
Yongqing Jiang and Yinfa Ma
Department of Chemistry and Environmental Research Center, Missouri University of
Science and Technology, Rolla, Missouri 65409

ABSTRACT

Modified nucleosides are formed at the post-transcriptional stage by chemical
modification of normal nucleosides within the RNA. These modified nucleosides cannot
be reutilized or further degraded, but they are excreted in the urine as intact molecules.
The elevated levels of modified nucleosides in the urine samples have been served as
potential cancer biomarkers in many studies. Even though different analytical techniques
have been reported for determining nucleosides levels, they are practically difficult to be
used as a routine tool for early cancer screening. In this paper, a novel method was
developed to separate and quantify 10 nucleosides (adenosine, cytidine, guanosine,
uridine, inosine, xanthosine, pseudouridine, N2-methylguanosine, 1- methyladenosine,
N2, N2-dimethylguanosine) in urine samples by using capillary electrophoresis with UV
detector at 254 nm. A 50 µm (i.d.) ×38cm (effective length) fused silica capillary was
used for the separation and a borate-phosphate buffer containing 25 mM CTAB at pH
9.50 was used as a background electrolyte. The separation was carried out at 15 kV under
reverse polarity and completed in less than 10 min. The linear range of the analytes was
from 5.0 to 500 µmol/L and the detection of limit was lower than 2.0 µmol/L. The effects
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of pH, buffer concentrations, CTAB concentration and the operation voltages on the
separation and quantification of the modified nucleosides were also investigated. The
technique, developed in this study, is much simpler and faster compared to previous
studies and can be used for quantifying modified nucleosides in urine samples.

KEYWORDS

Modified nucleosides; cancer biomarker; capillary electrophoresis

INTRODUCTION

Nucleosides are primary constituents of ribonucleic acids (RNAs). When RNAs
are biotransformed, the normal nucleosides can either be metabolized or reutilized to
synthesize nucleic acid. However, in particular cases, some RNAs are transformed into
modified nucleosides which can neither be further degraded nor reutilized, but are
excreted intact in urine as end products due to a lack of specific phosphorylases37. In
cancer disease where cell proliferation takes place, RNA metabolism increases
dramatically and higher concentrations of excreted modified nucleosides will be
observed. Consequently, the levels of modified nucleosides in urine can reflect RNA
degradation in the organism and so they can be used as potential cancer biomarkers.
Modified nucleosides in human urine as possible cancer biomarkers have been of
interest since 1970s. Some studies reported that elevated levels of some nucleosides in
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the urine samples can be served as potential cancer biomarkers and the urinary profile of
modified and normal nucleosides have been widely studied as markers of leukemia40,
breast cancer41-43, thyroid cancer 11, uterine cervical cancer 44, liver cancer 45, lung cancer
46

, bladder cancer and colorectal cancer 47,48, head and neck cancer 49, and rheumatoid

arthritis process50. Profiles of urinary nucleosides could also be used in monitoring
progress of the cancer disease and the response of individuals to an applied therapy51.
Nevertheless, no specific pattern has been discovered up to date. Searching for the
specific biomarker for specific cancer is very crucial for early cancer diagnosis. In many
cases, an efficient separation and determination technique is required to assess the levels
of these biomarkers.
Different analytical techniques have been reported for separating and determining
normal and modified nucleosides in urine samples, including immunoassays52, high
performance liquid chromatography (HPLC) and capillary electrophoresis conjugated
with UV detection53-58, photodiode-array detection55, and mass spectrometry (MS) 49, 59-62.
However, there is no routine cancer diagnostic tool based on levels of urinary nucleosides
in clinical laboratories. One reason is that there is no specific nucleoside as biomarker to
a specific type of cancer. Another major reason is due to the lack of practicable analytical
techniques to conveniently obtain levels of urinary nucleosides. Even though both
Immunoassay and HPLC have been demonstrated for analysis of nucleosides, the
procedures are tedious and the methods are time-consuming. In addition, HPLC
consumes a large amount of organic solvents and the organic is not environmental
friendly.

15
High-performance capillary electrophoresis (HPCE) has proven to be a rapid and
simple technique for separating charged biomolecules with very high resolution. Its
unique advantages, such as a relatively short time of analysis, high separation efficiency
with consumption of minimal amount of sample and buffer solutions, make HPCE a
valuable technique for determination of urinary nucleosides. Micellar electrokinetic
chromatographic (MEKC) methods with sodium dodecyl sulfate (SDS)–borate–
phosphate buffer have been applied for determination of urinary nucleosides by many
researchers 11, 44, 56, 63. However, it was found that the method had a long separation time
and the SDS in the background electrolyte (BGE) caused a poor reproducibility due to the
frequent generation of air bubbles in the separation column. In this paper, we have
developed a simple and fast HPCE method for the determination of urinary nucleosides
using Na2B4O7 - NaH2PO4 as BGE and cetyltrimethylammonium bromide (CTAB) as
BGE additive. The reproducibility and migration time were greatly improved. The
optimized method has been used for analysis of 12 important urinary nucleosides from
both normal and breast cancer-carrying subjects. The main goal of this study was to
develop a fast and reproducible HPCE method to study modified nucleosides that present
in urine samples from both cancer-carrying patients and healthy controls, so that it can be
used to provide nucleoside profile information for potential early cancer screening.
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MATERIALS AND METHODS

Chemicals
12 nucleoside standards, including adenosine, cytidine, guanosine, uridine,
inosine, xanthosine, pseudouridine, N2-methylguanosine, 1- methyladenosine, N2,N2dimethylguanosine, 8-hydroxy-2‘-deoxyguanosine, 5-hydroxymethyl-2‘-deoxyuridine,
and creatinine (for normalization purpose) were purchased from Sigma–Aldrich (St
Louis, MO, USA). All other chemicals used for the background electrolyte preparation
and capillary rinsing, such as sodium phosphate, sodium tetraborate, CTAB, methanol,
sodium hydroxide and hydrochloric acid, were also obtained from Sigma–Aldrich (St.
Louis, MO, USA). Deionized water (18.2 MΩ) from Millipore Simplicity 185 - system
(Millipore, MA, USA) was used to prepare standard solutions, BGE and other solutions.

Preparation of BGE
The BGE solution containing 25 mM Na2B4O7, 25 mM NaH2PO4 and 25 mM
CTAB was prepared with deionized water and the pH was adjusted to 9.50 by adding 1.0
M NaOH in the buffer before diluting it to the final volume. The buffer solution was
filtered through the 0.45µm membrane filter before use.

Preparation of Standard Nucleoside Solutions
The 10 mM stock solutions of adenosine and xanthosine were prepared in 1.0 M
NaOH and guanosine was in 50% formic acid. The 10 mM stock solutions of other
nucleosides were prepared in deionized water. All stock solutions were kept at −20 oC.
The working nucleoside solutions were prepared by diluting the stock solutions with
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deionized water to the concentration range of 1–5000 µM (1, 5, 10, 50, 100, 500, 1000
and 5000).

Preparation of Urine Samples
Spontaneous urine samples from one healthy adult and one breast cancer patient
were collected from the Ellis Fischel cancer center (Columbia, MO). After collection, the
samples were frozen and stored at −80 oC immediately. Before the analysis, the samples
were thawed at room temperature. Each urine sample was prepared for both nucleosides
and creatinine analysis.
Nucleosides were extracted from urine samples through affinity chromatography
gel as described in the literature44. Basically, each of 3 mL extraction (SPE) tube
purchased from Supelco (Bellefonte, PA, USA) was packed with Affi-gel 601 (200 mg).
The gel was conditioned by washing sequentially with 15 mL 0.1 M formic acid in 50%
methanol and 0.25 M ammonium acetate (pH 8.6) prior to be used as phenylboronic acid
(PBA) columns for SPE in affinity mode. 25% ammonia was added to urine samples to
adjust pH to the range of 8.2 to 8.6 and then centrifuged. For the analysis of nucleosides,
1 mL supernatant was loaded to a preconditioned PBA column, followed by the addition
of 0.5 mL 0.25 M ammonium acetate (pH 8.6) and standing for 5–10 min. The PBA
column was then successively rinsed with 4.0 mL 0.25 M ammonium acetate (pH 8.6),
0.3 mL 50% methanol twice and 0.5 mL 0.1M formic acid in 50% methanol. The rinsed
column was eluted with 3 mL 0.1M formic acid in 50% methanol. The eluent was
evaporated to dryness in the Turbovap LV evaporator (Zymark, Hopkinton, MA, USA) at
50 ºC, and then the residue was dissolved in 200 µL water for HPCE analysis. For the
creatinine analysis, a method developed by Yufang Zheng etc. was used with minor
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modification64. Briefly, the urine supernatant was diluted 8-fold in deionized water and
then injected to CE column for direct analysis.

Instrumentation
All CE experiments were carried out on a Beckman Coulter P/ACE MDQ
instrument (Beckman Instruments, Fullerton, CA, USA) equipped with a UV-absorbance
detector. Electrophoretic data were acquired and analyzed by 32 Karat software version
4. Separations were performed in fused silica capillaries (Polymicro Technologies,
Phoenix, AZ) with 50µm (i.d.) × 38cm (effective length). New capillaries were
conditioned by rinsing with methanol for 15 min, deionized water for 5 min, 1.0 M HCl
for 5 min, followed by deionized water for 5 min again, then 1.0 M NaOH for 20 min and
deionized water for 5 min. The capillary was rinsed with deionized water for 5 min and
then pre-run with BGE for 20 min under -15 kV every morning to obtain the best
reproducibility. Samples were injected into the capillary at 0.5 psi for 10 s. After each
analysis, the capillary was rinsed successively with 0.1 M NaOH for 1.0 min, deionized
water, and BGE for 2.0 min respectively. Nucleosides separation was carried out at -15
kV at 25 ºC and the wavelength of the UV detector was set at 254 nm. For the analysis of
creatinine, 30 mM phosphate at pH 6.0 was used as BGE and the separation was
completed under 15KV with the detection wavelength at 214 nm. Other conditions were
the same as those of nucleosides.
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RESULTS AND DISCUSSION
Nucleosides are suitable to be analyzed by capillary electrophoresis56, due to their
negative charges in a wide pH range, diverse molecular weight, and hydrophilic property.
The quality of the electrophoretic separation and the time required for this separation
depend on a number of analytical parameters, such as running buffer composition and
pH, buffer concentration and additives, the applied voltage, the length and diameter of the
capillary, and the sample size introduced, and so on. All these conditions were
investigated systematically in this study in order to get the optimum separation
conditions. Figure 1 showed the separation of 12 nucleoside standards under optimal
conditions by using HPCE. The running buffer was composed of 25 mM Na2B4O7 + 25
mM NaH2PO4+ 25 mM CTAB (pH=9.50) and the separation voltage was -15 kV with
UV detection at 254 nm.

Effect of Buffer Concentration
Tetraborate, which can form complex network with hydroxyl group, has been
used to improve the separation of catechols, carbohydrates and nucleosides53, 65, 66.
After preliminary experiments, an electrolyte containing tetraborate, phosphate and
CTAB was selected as the running buffer. Five different tetraborate concentrations (15,
25, 50, 75 and 100 mM) were examined to compare the separation efficiency and peakto-peak resolutions of 12 nucleosides. With the increase of the tetraborate concentration
above 25mM, the migration time became longer and longer without any improvement of
the nucleoside separations. When the concentration was decreased to 15mM, the
resolution was getting worse and several peaks merged together and cannot be separated.
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Figure 1. Electropherogram of 12 nucleoside standards at optimized conditions by HPCE
with UV detection at 254nm. Capillary: 50µm (i.d.) × 48cm (38 cm to detection
window); Applied voltage: -15KV; Temperature: 25℃; Sample injection: 0.5psi for 10s;
Running buffer: 25 mM Na2B4O7 + 25 mM NaH2PO4+ 25 mM CTAB, pH=9.50; Peak
identification: 1, adenosine (A), 2, cytidine (C), 3, guanosine (G), 4, uridine (U), 5,
inosine (I), 6, xanthosine (X), 7, pseudouridine (Pseu), 8, N2- methylguanosine (m2G), 9,
N1-methyladenosine (m1 A), 10, 8-hydroxy-2‘-deoxyguanosine, 11, 5-hydroxymethyl-2‘deoxyuridine, 12, N2,N2 -dimethylguanosine (m22G).

Meanwhile, the current went up significantly at higher buffer concentrations and the
Joule heating generated affected the separation. Therefore, the optimized tetraborate
concentration was maintained at 25 mM. Phosphate was used as co-ion because of its UV
transparency at 254 nm. After a series of experimental studies, 25mM was chosen as the
optimal concentration. Under this condition, the current was about 60 µA at 25ºC, which
did not produce significant amount of Joule heating. The running buffers were replaced
every 12 runs to keep the ionic strength balanced on both sides of the running buffer, so
that reproducible data can be obtained.
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Effect of Buffer pHs
The most crucial parameter for the nucleoside separation by using HPCE is the
pH of the running buffer. It not only affects the solute charge, but also influences the
capillary wall surface and will cause a concomitant change in electroosmatic flow (EOF).
Most nucleosides, with cis-diol structures, will bind with boric acid at high pHs and form
negatively charged complex67. Therefore, four different pH values (9.02, 9.32, 9.50 and
9.78) were examined for the separation of 12 nucleosides. The results were shown in
Figure 2. It was clearly shown that the HPCE separation of nucleosides was very
sensitive to pHs. Under pH 9.02, pseu and U, X and C, and G and A coeluted with each
other, respectively. In addition, m22G coeluted with system peak. As pH increased to
9.32 or above, m22G eluted after the system peak. With the increase of the pH to 9.50,

Figure 2. The pH effect on the separation of 12 nucleoside standards. The experimental
conditions were the same as those of Figure 1, except for the pHs of the running buffer.
Peak identifications were the same as those in Figure 1.
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the migration time became longer but the resolution also increased and all 12 nucleosides
can be well separated. When the running buffer pH increased to 9.78, X and C couldn‘t
be well separated. For the examined pHs, these 12 nucleosides can only be separated at
9.50. It was clear to see that the nucleosides have different mobilities at about pH 9.50
under the present separation conditions. Therefore, the optimal pH for the separation of
these 12 nucleosides was set at 9.50.

Effect of Additive Concentration
Additives are widely used in HPCE separations acting as solubilizing agents for
hydrophobic solutes or as wall modifiers. For the separation of nucleosides, SDS has
been used as surfactant at 300 mM in most of the studies to help improving the
separations. However, several problems have been encountered by adding SDS in the
running buffer: (1) bubbles were easily generated at such a high surfactant concentration,
(2) relatively long separation time (normally 30~40 min) and pH shifting were observed,
and (3) poor reproducibility after 3 runs and noisy baseline were often obtained. Without
additives, these nucleosides couldn‘t be well separated because of their close PIs.
Therefore, CTAB was used in our study to help the separation. CTAB, which is a cationic
surfactant, was used to cover the silanol groups and make the capillary wall positively
charged in order to prevent positively charged particles from adsorbing on the wall. In
addition, the use of CTAB in this method also reversed the direction of the EOF and form
micelle simultaneously at above CMC (1.3 mM), which helped in the nucleoside
resolution. Moreover, the presence of CTAB as an additive enhanced the interaction
between BGE and nucleosides, predominantly anionic species, improving the nucleoside
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separation. Total of seven CTAB concentrations (5, 10, 15, 25, 50, 75, and 100 mM)
were examined in our study and the results are shown in Figure 3. Under the CTAB
concentrations below 25mM, only 11 peaks were observed and m2G and m1 A merged
together, although the migration time was shorter. At 50 and 75 mM CTAB
concentrations, m22G co-eluted with the system peak. When CTAB concentration reached
to above 100 mM, crystals were found in the running buffer after one day. Therefore, 25
mM CTAB was chosen as the buffer additive in this study and the separation of 12
nucleoside standards can be completed in 7 min.

Figure 3. Effect of CTAB concentration on the separation of 12 nucleoside standards.
The experimental conditions were the same as those of Figure 1, except for the CTAB
concentrations. Peak identifications were the same as those in Figure 1.

24
Effect of Applied Voltage
Three voltages (20, 18 and 15 kV) were examined in our study. Under 20 and 18
KV, X and C cannot be separated and merged as a single peak and m1 A also was hidden
in I. Although the migration time was longer at 15 kV, the peak resolution was greatly
improved within the reasonable time. Therefore, 15 kV was selected as the optimized
separation voltage in our study.

Linearity, Detection Limit, Reproducibility, and Recovery study
Completely study of linearity, detection limit, reproducibility, and recovery of
modified nucleosides of this HPCE method was conducted and the data were summarized
in Table 1 and Table 2. Since this method can also be used to determine the nucleoside
levels in other biological samples, CE and SPE methods were validated separately. In the
linearity study, nucleoside concentrations selected were based on the expected
concentration range in the urine samples. The following concentrations in DI H2O were
used to construct the calibration curves: 0, 5, 10, 25, 50, 100, 250, 400, 500 µM for A, C,
G, U, X, I, m22G, m1A; 0, 10, 25, 50, 100, 250, 500, 1000 µM for m2G, 8-hydroxy-2‘deoxyguanosine and 5-hydroxymethyl-2‘-deoxyuridine; 0, 50, 100, 200, 400, 1000,
2000, 5000 µM for pseu; and 5, 20, 100, 1000, 2000, 5000 µM for creatinine. The
regression parameters such as linearity range, slope, intercept and correlation coefficients
are presented in Table1. The averages of the correlation coefficients for six injections
were between 0.9843 to 1.0000, which indicates a good linearity. The limit of detection
(LOD) of this method was defined as the concentration where the ratio of signal to noise
was 3. As listed in Table 1, the limit of detection of this method is from 0.56 to 1.67 µM,
which is sensitive enough for nucleoside detection in urine samples.
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Table 1. Linearity and detection limit of nucleosides and creatinine. The
experimental conditions were the same as those of Figure 1.
Linear
Nucleosides

range
(µM)

Slope

Limit of

(peak

confidence

area/µM

for slope

)

(p=95%)

Intercept
(peak
area)

Pseu

50 -5000

30.3

26.9 -33.7

11.5

U

10 -400

65.8

60.8 -70.8

-46.5

X

5 - 500

82.4

80.9 -83.8

1.64

C

5 - 400

70.7

65.9 -75.5

-74.3

G

5 - 250

88.4

84.8 - 91.9

-43.8

A

5 - 500

94.7

88.0 - 101

-66.4

I

10 -400

128

117 -138

-52.8

m1A

10 -500

88.8

88.6 -88.9

-59.5

11*

10 -500

75.3

74.4 -76.1

-20.4

10*

10 -500

116.7

95.9 -137

118

m2G

10 -1000

74.0

67.3 -80.6

-7.69

m22G

5 - 500

79.0

75.7 - 82.2

-8.38

Creatinine

5 -5000

0.068

0.065 -0.071

-0.99

Limit of
confidence
for intercept

R2

LOD
(µM)

(p=95%)
-83.6 -107

0.994

0.67

0.997

1.06

0.999

0.78

0.998

1.67

0.999

0.77

-254 - 121

0.998

1.09

-345 - 239

0.997

0.56

1.00

0.76

1.00

0.98

-467 - 703

0.996

0.55

-196 - 180

0.997

1.26

0.984

0.74

0.999

0.89

-187 93.7
-38.7 –
42.0
-209 60.4
-144 56.3

-65.0 - 54.1
-44.2 3.31

-88.6 71.9
-7.0 -5.1

*10, 8-hydroxy-2‘-deoxyguanosine; 11, 5-hydroxymethyl-2‘-deoxyuridine.

26
Table 2. Reproducibility and Recovery for nucleosides and creatinine*
Nucleosides

RSD (%)

Recovery (%)

Pseu

3.6

108

U

7.2

104

X

7.9

82.6

C

6.4

113

G

6.8

83.8

A

5.7

92.9

I

8.3

81.2

1

mA

7.2

89.4

5-hydroxymethyl-2‘-deoxyuridine

N/A

0

8-hydroxy-2‘-deoxyguanosine

N/A

0

m2G

5.1

105

m22G

6.7

108

Creatinine

4.1

95.6

*The experimental conditions were the same as those of Figure 1.
N/A- not applicable

The reproducibility of relative peak areas, which is expressed as a percentage of
relative standard deviation (RSD), was determined by six consecutive analyses of the
normal urine sample. As showing in Table 2, the developed method was reproducible and
these nucleosides were very stable during the analysis. The good reproducibility is not
only due to the usage of CTAB as additive, but also due to the capillary rinsing procedure
at the beginning of each day and the one between runs.
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The recoveries of the nucleosides were determined by spiking the standards into a
1.0 mL urine sample. From the data in Table 2, we can see that the recoveries for both 8hydroxy-2‘-deoxyguanosine and 5-hydroxymethyl-2‘-deoxyuridine were 0, which means
they were not extracted by the affinity gel used in this study. While phenylboronate
affinity chromatography selectively binds the cis-diol groups available on the nucleoside
ribose sugar, the missing hydroxyl functional groups on the 2‘ position for 8-hydroxy-2‘deoxyguanosine and 5-hydroxymethyl-2‘-deoxyuridine makes these two nucleosides not
have cis-diol structures any more. Therefore, the present nucleoside extraction method
from urine may not be applicable to the non-cis-diol nucleosides. Therefore, the sample
preparation method becomes the limiting step of the whole nucleoside analysis by using
this newly developed fast CE separation method. For the rest of 10 nucleosides, a range
of 81.2% to 113% recovery were obtained, which is acceptable.

Analyses of Urine Samples
In order to demonstrate the applicability of the developed method, it was applied
to two urine sample analyses collected from a healthy person and a breast cancer patient.
A capillary electropherogram of nucleosides in the urine extract from the healthy person
is shown in Figure 4. The average nucleoside levels excreted in urine samples from a
non-cancer carrying person and a cancer patient were shown in Table 3. The peaks were
identified by comparing migration times of the unknown peaks with those of the standard
nucleosides eluted under the same condition, and by spiking the urine sample with pure
single nucleoside standards. The levels of the urinary nucleosides were calculated by
using standard calibration curves, and then were transformed into nM nucleoside/µM
creatinine. Creatinine has been used in many clinical studies as internal standard since its
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concentration strictly corresponds to urine dilution. Many studies have shown that
urinary nucleosides excretion from human beings is little affected by diet, and when
normalized to urinary creatinine, the daily excretion rate is remarkably constant in an
individual 57, 68. The results obtained through our newly developed HPCE-UV method
were comparable to those of previous CE-UV method and HPLC method. More urine
samples will be analyzed by using this newly developed method for potential early cancer
screening using nucleosides as biomarkers.

Figure 4. A representative electropherogram of nucleosides in a urine extract of a healthy
subject. The experimental conditions and peak identifications were the same as those of
Figure 1.
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Table 3. Average nucleoside levels excreted in urine samples from a normal
subject and a breast cancer-carrying patient (nM nucleoside/µM creatinine)
Nucleosides

Normal subject mean Cancer patient mean

Literature data for normal

± SD

± SD

subject43, 44, 50, 63, 69-71

Pseu

24.0 ± 3.2

48.2 ± 2.4

13.0~42.0

U

1.01 ± 0.10

1.22 ± 0.08

0.21~0.99

X

0.76 ± 0.04

1.30 ± 0.09

0.24~0.86

C

0.57 ± 0.29

7.55 ± 0.62

0.01~0.78

G

10.0 ± 0.1

11.7 ± 1.0

0.01~10.70

A

3.51 ± 0.21

6.09 ± 0.18

0.18~4.70

I

7.38 ± 0.59

12.3± 0.2

0.09~8.80

1

mA

3.01 ± 0.23

3.34 ± 0.31

2.02~2.90

m2G

0.59 ± 0.01

2.46 ± 0.14

0.26~2.00

m22G

0.32 ± 0.01

2.03 ± 0.32

0.36~1.74

CONCLUSION

A simple and fast HPCE method was developed for separation and quantitation of
10 modified nucleosides in urine samples. The separation time was reduced dramatically
and the reproducibility was significantly improved, compared to previous CE and HPLC
methods, which is very valuable for clinic diagnosis. The factors that affect separation
efficiency, such as pH, voltages, buffer composition and concentrations, have been
systematically investigated and optimized. This method can be used for urinary
nucleoside determination for early cancer screening in which nucleosides are used as
biomarkers.
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ABSTRACT

Current prostate cancer (PCa) diagnosis, based on the triad of digital rectal
examination (DRE), blood prostate-specific antigen (PSA) level measurement and trans ultrasound guided prostate biopsy, is not a precise science. The widely used PCa
biomarker PSA has poor sensitivity and specificity, leading to false-negative and falsepositive test results. Recently, sarcosine, proline, kynurenine, uracil and glycerol-3phosphate were found in large concentrations in metastatic prostate cancer urine samples.
By measuring all these five metabolites, doctors may be better able to diagnose prostate
cancer with high accuracy. However, there is no method reported to detect these
compounds in urine sample simultaneously. In this paper, a novel method was developed
to separate and quantify 6 metabolites including creatinine in urine samples by using
liquid chromatography with tandem mass spectrometry. Chromatographic characteristics
of the analytes were determined using a phenyl-hexyl column with 0.1% formic acid in
water and acetonitrile respectively under a gradient program. The six metabolites were
detected in the multiple reaction monitoring (MRM) modes with ESI-positive mode. The
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linear range of the analytes was from 0.0026 to 44.6 µmol/L and the detection of limit
was lower than 2.61 nmol/L. The effects of stationary phase, mobile phase and mass
spectrometry on the separation and quantification of the six metabolites were also
investigated. The technique developed in this study is simple, fast, sensitive and selective
and will be used for quantifying these six metabolites in urine samples for potential early
cancer screening.

KEYWORDS

Sarcosine; prostate cancer biomarker; LC-MS/MS

INTRODUCTION

Prostate cancer (PCa) ranks as the third most common cancer in men in the
world72,73. In US and Europe, PCa is the most common cancer diagnosis and the second
most common cause of cancer-related deaths in men74. Furthermore, the disease
incidence is increasing steadily over the years, although its etiology remains unknown.
However, prostate cancer diagnosis is not a precise science yet. Normally, the screening
of PCa is based on the triad of digital rectal examination (DRE), blood prostate-specific
antigen (PSA) level measurement and trans-ultrasound guided prostate biopsy75,76. The
typical exam combines a digital probe of the prostate to check for swelling or lumps and
a blood test to reveal PSA levels. If an abnormal DRE and/or PSA levels are found, a
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prostate biopsy is often recommended. The definitive diagnosis of cancer is based on
histological assessment of the needle biopsy tissue material77. Although, DRE allows the
clinician to ―feel‖ the prostate, it has a poor sensitivity and typically only allows the
detection of relatively large tumors which usually represent locally advanced disease.
Even when a biopsy reveals cancer, it sometimes remains unclear whether the cancer is
aggressive and at risk of spreading, or indolent. Biopsy doesn‘t always reveal the true
disease condition. Therefore, biomarkers are needed for the prostate cancer diagnosis.
Currently, PSA is the only biomarker widely used in the diagnosis and
management of patients with PCa. However, it has poor sensitivity and specificity for
cancer detection, leading to false-negative and false-positive test results. Also, PSA is
unable to distinguish indolent from aggressive tumors. The results is nearly 30,000 men
die of prostate cancer in the United States each year, but millions of others who have the
disease are not even aware of it 78. Many men with indolent disease are overtreated and at
the same time aggressive cases are not caught. Thus, more and more researchers began to
question PSA as PCa biomarker79. There is an urgent need for clinically validated
biomarkers which will improve the diagnosis and management of PCa.
In 2009, sarcosine, an N-methyl derivative of the amino acid glycine, was
revealed to highly increase during prostate cancer progression to metastasis and can be
detected non-invasively in urine 39. Four other metabolites, including proline, kynurenine,
uracil and glycerol-3-phosphate, were also found in large concentrations in metastatic
prostate cancer by the same research team. However, only sarcosine was currently
studied for the potential role in prostate cancer progression. In our work, we proposed
that five metabolites, including sarcosine, proline, kynurenine, uracil and glycerol-3-
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phosphate, can be used as a biomarker panel and doctors might be better able to diagnose
prostate cancer and its progression by using this panel. During the biomarker
confirmation and early cancer screening, a simple but powerful separation and
quantification technique is crucial.
The structures of the five metabolites and creatinine (for normalization purpose)
are shown in Figure 1. From Figure 1 we can see that five of the molecules are amines.
The determination of molecules carrying amine groups is usually performed by ionexchange chromatography followed by post column derivatization and then detected by
mass spectrometer or UV80. Some studies use pre-column derivertization and then
analyze the analytes by MS81-83. Isotope dilution method coupled with LC-MS or GC-MS
has also been employed by some researchers84, 85 and samples need to be modified to
their t-butyl dimethylsilyl derivatives before analyzed by mass detector. However, the
above mentioned analytical techniques are complicated, time-consuming and have high
requirement to the operating person. These problems will prevent the findings from being
applied to the clinic and new method needs to be developed.
Tandem mass spectrometry (MS/MS) is a powerful technique for the quantitative
analysis of small molecules. The combination of the specific parent mass and the unique
fragment ion is used to selectively monitor for the compound to be quantified. When it is
conjugated with HPLC, most ions and other components from the sample matrix
suppressing the signal output are removed and potential isobars are separated. HPLCMS/MS facilitates the sensitive and specific analysis, especially in complex matrices like
urine and blood. In recent years, the use of HPLC-MS/MS has become more popular in
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hospital laboratories and is applied to the quantitative analysis of small molecules such as
metabolites and pharmaceuticals86.

Sarcosine

Proline (Pro or P)

Creatinine

Kynurenine

Uracil

Glycerol 3-phosphate

Figure 1. Structures of six molecules

In this paper, a robust HPLC-MS-MS technique was developed to separate and
quantify six molecules simultaneously in a single run. Simplicity of sample preparation,
short analysis time and super specificity and sensitivity of this method make it suitable
for biomarker screening using urine samples. Healthy subjects, prostate cancer and other
cancer patients‘ urine samples were analyzed using the newly developed method. The
main goal of this study was to establish an efficient analytical technique to
simultaneously measure the six compounds that are present in urine samples from both
cancer-carrying patients and healthy controls, and therefore provide a key tool for new
prostate cancer biomarker identification and confirmation. More urine sample analyzing
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is ongoing by using the established method, new cancer biomarkers will be confirmed
and potential early cancer screening can be conducted based on these findings.

MATERIALS AND EXPERIMENTS

Chemicals
Six metabolite standards, including sarcosine, proline, kynurenine, uracil,
glycerol-3-phosphate, and creatinine (for normalization purpose) were purchased from
Sigma–Aldrich (St Louis, MO, USA). L-Glutamine isotope which was used as internal
standard for LC-MS/MS analysis was obtained from Cambridge Isotope Laboratories
(Andover, MA, USA). Formic acid (99%) and LC-MS grade acetonitrile which were
used to prepare mobile phase were purchased from Sigma-Aldrich (St Louis, MO, USA).
LC-MS grade water (18.2 M ) from ultra-high purity water system from Millipore Inc.
(Millipore, MA, USA) was used to prepare standard solutions, mobile phase and other
solutions.

Urine Sample Collection and Preparation
Spontaneous urine samples from 10 healthy adults, 7 prostate cancer patients and
3 other cancer patients were collected from Missouri University of Science and
Technology (Rolla, MO, USA), the Ellis Fischel cancer center (Columbia, MO, USA),
and Central Missouri Urology Clinic (Rolla, MO, USA). After collection, the samples
were frozen and stored at -80oC immediately. Before analysis, samples were thawed at
room temperature and then diluted 3 times using water. 10 μL of diluted urine was mixed
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with 10 μL of the internal standard solution and 1480 μL of 0.1% formic acid in water.
The sample was then ready for LC-MS-MS analysis.

High-Performance Liquid Chromatography (HPLC)
Agilent 1100 series LC system (Santa Clara, CA) and a phenyl-hexyl, 3.0 μm,
3.0×150 mm column (Phenomenex, USA) were used to conduct the metabolite
separation. Liquid chromatography was performed at 25°C under a flow rate of 250
μL/min using a gradient system with the mobile phase consisting of A: 0.1% formic acid
in water and B: 0.1% formic acid in acetonitrile (100%). The gradient program was:
initial 98% A and 2% B; linear gradient to 60% A and 40% B in 5 min; return to initial
conditions in 0.1 min at a flow rate of 250 μl/min, followed by equilibration for 10 min.
Run-to-run time was 15 min. The injected volume was 10 μL.

Tandem Mass Spectrometry (MS/MS)
API 4000Q trap MS/MS system (Applied Biosystems, Foster City, CA) was used
to detect the molecules. Mass spectrometer was operated in multiple-reaction monitoring
mode (MRM) under the ESI-positive mode. Turbo Spray was used as the ion source. The
capillary voltage was set at 5.5 kV. Nitrogen gas was used as curtain gas and cone gas.
The cone gas flow was 50 L/h and the desolvatation gas flow was 800 L/h. Optimal
detection conditions were determined by direct infusion of each standard solutions (20
ppb) in solvent A using a syringe pump. Parent-ion and daughter-ion scans were
performed using argon as the collision gas at a pressure of 3.8×103 mbar and a flow of
0.2 mL/min.
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Data Normalization
Human biological samples, such as urine, exhibit a large amount of variation
caused by physiological factors such as sex, state of health, age, diet, stress, or diurnal
cycles among others. The experiment data thus require normalization to account for the
variation and to give each sample equal importance in analysis by multivariate statistics.
All the metabolite experiment data was normalized according to creatinine concentration
in this study.

Method Validation
Because of the number of analytes and complexity of the sample matrixes,
linearity and limit of quantification (LOQ) were determined by spiking 3 independent
urine samples with known concentrations of the analytes. LOQ was chosen as the lowest
standard on the matrix-based calibration curve. Reproducibility and accuracy were
determined by 5 consecutive analyses of spiked urine sample at low, middle and high
analytes concentrations. This ensured that the precision and accuracy can be assessed for
all studied metabolites at all levels.

RESULTS AND DISCUSSION

A quantitative assay should be specific, accurate and sensitive. The method
development time should be as short as possible without sacrificing the above
attributes. Assays based on mass spectrometry quantitation combined with HPLC
separation can satisfy these criteria if the conditions are optimized. It is realized that
parameters related to sample pretreatment, chromatography, analyte ionization, and mass
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spectrometric analysis are all strongly interrelated and will significantly affect the quality
of separation and quantification of the developed technique. These important issues are
discussed below.

Sample Preparation
A wide variety of sample pretreatment methods have been applied in quantitative
bioanalysis using LC-MS, including liquid-liquid extraction, solid phase extraction
(SPE), or protein precipitation87. Compared to the fast MS analysis, some sample
pretreatment methods are tedious and time-consuming and therefore limit the analysis
efficiency. In this study, less time need be spent on sample preparation because of the
combination of high selectivity and sensitivity of tandem mass and high separation
performance of HPLC. The samples only need to be diluted 450 times and then ready for
LC-MS/MS analysis. Because of the use of HPLC, most interference from the matrix was
removed before MS/MS quantification. The high sensitivity of tandem MS enables us to
detect the interest analytes after dilution with aqueous phase and the high selectivity
ensures that without extraction and other pretreatment method, the analytes can still be
detected without interference. This eliminating the need for extensive sample preparation
and hence reducing the effort spent on method development and routine analysis will
save a lot of time and money in bioanalysis.

Optimization of Liquid Chromatography Conditions
Although tandem MS can surmount some chromatographic problems, good
chromatography will give better quantification and calibration curves. So it is better to
separate component peaks with LC than with the MS. If components are separated well
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on the column, more time per component can be used to scan resulting in better signal to
noise ratios. Better signal to noise ratios are easier to integrate, give better
reproducibilities and also an increase in sensitivity. Also, co-elution might cause
competition effects during the ionization. In our study, the optimized liquid
chromatography conditions were chosen based on the interested analytes and all six
metabolites including creatinine are completely separated, as shown in Figure 2.

Figure 2. A representative chromatogram of 6 metabolites standards at optimized
conditions by HPLC-MS/MS. Column: 3.0 μm, 3.0×150 mm (phenyl-hexyl);
Temperature: 25°C; Flow rate: 250 μL/min; Injected volume: 10 μL; Mobile phase A:
0.1% formic acid in water and B: 0.1% formic acid in acetonitrile (100%); Gradient
program: initial 98% A and 2% B; linear gradient to 60% A and 40% B in 5 min; return
to initial conditions in 0.1 min at a flow rate of 250 μl/min, followed by equilibration for
10 min; Run-to-run time was 15 min; MS/MS conditions are the same as that in Table 1.
Peak identification: 1, Glycerol 3-phosphate (G3P), 2, Creatinine (CRE), 3, Sarcosine
(SAR), (G), 4, Proline (PRO), 5, Uracil (URA), 6, Kynurenine (KYN).
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From the analytes structures which are shown in figure 1, we know that four of
them are polar and at the same time five of the metabolites are amines except glycerol
phosphate. Currently, metabonomics studies with LC-MS predominantly use reversedphase (RP) chromatography, in which C18 column conducts the separation most of the
time88, 89. Although C18 column is very common, it is not suitable to retain and therefore
separate highly polar analytes. A commonly used strategy to separate polar compounds
by C18 column is to add ion-pair reagent in the mobile phase90. Tridecafluoroheptanoic
acid (TDFHA) as additive was tested in our study. However, the small hydrophilic
molecules, sarcosine, proline, glycerol-3-phosphate and creatinine, had no retention on
column and couldn‘t be separated. They were eluted out the column quickly with matrix.
Also, ion-pair reagent bleeding, column block and bad reproducibility problems were
also observed. Phenyl-hexyl column, which can provide excellent retention for aromatic,
polar and amines under pH=1.5 ~ 10, was therefore used in our study. Compared with
C18 column, phenyl-hexyl column revealed good separation for our analytes, which is
shown in Figure 3.
In HPLC, one of the eluent components is water and another component of any
binary eluent is organic solvent. ACN is used as organic phase in this study because of its
higher solvent strength and lower viscosity than MeOH in mixtures with water. 0.1%
formic acid was added to both aqueous and organic phase for better peak shape and high
ionization efficiency purpose.
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Figure 3. The separation comparison of 6 metabolites standards between C18 and Phenylhexyl column. Other conditions are the same as that in figure 2.

Gradient program was optimized using the so-called 60/60. That is, near 0% B to
60% B was run first in 60 minutes and the chromatographic character of the studied
compounds on the column was learned. Under 60% B, all analytes were eluted out the
column. Then both B% and time were decreased subsequently until they reached 40% B
at 5 minutes where complete separation could still be obtained. Decreasing the elution
time and B% further couldn‘t get good separation any more. In order to let the
compounds stack on the front of the column, give sharp peaks and get better separation
through long column path, 98% aqueous phase at the beginning of gradient program was
our choice. We didn‘t start the program at 100% aqueous phase and 0% organic phase,
because the alkyl chains of the stationary phase would get away from the high aqueous
environment, mat down on the particle and not efficient at capturing the analytes if we
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did so. Therefore, the gradient program was started with small percentage of organic
phase - 2% in this study.

Optimization of MS/MS Conditions
HPLC coupled to mass spectrometry (MS) is increasingly being used for urinary
metabonomic studies. Mass spectrometry is a highly sensitive but selective technique.
Used in conjugation with HPLC, which provides separation of the components, mass
spectrometry allows detection and quantification of low-level metabolites91.
In order to develop a MS/MS method, each parameter could have been optimized
for each compound. However, for source/gas parameters, such as curtain gas, collision
gas, ion spray voltage and ion sources, quite similar values were obtained for them. In all
cases, their variation did not lead to a significant variation in the intensity of the signal
(data not shown). Thus, same parameters were chosen for all compounds as shown in
materials and experiments part in this study.
For other parameters, it was necessary to establish for each molecule their own
ones. For example, DP applied to the interface is specific for each precursor ion, and CE
is specific for each fragment ion. For this purpose, 20 ppb standard solutions of each
compound were infused by syringe pump into the mass spectrometer under similar flow
rate and mobile phase components to that in chromatography so that the actual sample
analysis condition was simulated. The most abundant and specific transition was selected
for use in the multiple reaction monitoring (MRM) mode with positive polarity. When
choosing the precursor/daughter ion pair, caution was applied in order not to choose the
too close pairs since the molecular weight are pretty close for some analytes. The
parameters were obtained and shown in Table 1 with the precursor/daughter ion masses.
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The specificity of the MS/MS method is linked to the combined analysis of the precursor
ion and one of its fragments. This technique is much more sensitive than others. Other
transitions characteristic of each molecule can also be used for confirmation of results, if
necessary.

Table 1. MS/MS parameters for 6 molecules including creatinine.
Analytes

Q1

Q3

Sarcosine

89.9

44

120

26

10

21

6

Proline

115.939

70.2

120

41

10

23

12

Kynurenine

209.014

94.1

120

36

10

21

4

Uracil

112.906

70

120

67

10

25

12

173

99

120

56

10

19

18

Creatinine

113.949

44.1

120

1

10

29

6

Glutamine (IS)

148.027

130

120

31

10

15

8

Glycerol-3phosphate

Dwell(ms) DP(V) EP(V) CE(V) CXP(V)

In order to get good mass quantification, several strategies were also used, such as
using fresh solvent weekly when analyzing samples, getting sharp peaks as best as we
can, not using nonvolatile buffer, acid and base, additives such as TFA and ion-pair
reagents, and using good IS (far enough from non-labeled analytes). In this study, LGlutamine isotope was used as an internal standard. It not only controlled HPLC
injection and ionization variability, also corrected the matrix effect of urine.
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Method Validation
Complete study of linearity, limits of quantification, reproducibility, and accuracy
of the six compounds using HPLC-MS/MS method was conducted in urine matrix and
the data were summarized in Table 2 and 3. In the linearity study, calibration curves were
prepared by spiking 3 urine matrixes with known concentrations of the analytes and the
average was taken. Concentrations of standards were chosen on the basis of the expected
concentration range in urine samples. The analyte concentrations in unknown samples
were estimated by shooting unknown samples along with low, middle and high standards.
The regression parameters such as linearity range, slope, intercept and correlation
coefficients are presented in Table 2. The correlation coefficients were between 0.9986
and 0.9999 (R2 > 0.99), which indicates a good linearity. The lowest standard on the
matrix-based calibration curve was selected as the limit of quantification and also the
analytes response at the LOQ was more than 5 times the response compared to blank
response. As listed in Table 2, the limit of quantification of this method is from 2.61 to
17.7 nM, which is sensitive enough for these six molecules detection in urine samples.
The reproducibility of relative peak areas, which is expressed as a percentage of
relative standard deviation (RSD), and the accuracy were determined by 5 consecutive
analyses of urine sample at low, middle and high analytes concentrations. This ensured
the possibility of precision and accuracy assessment for all studied metabolites at all
levels. As showing in Table 3, the developed method was reproducible and these
metabolites were very stable during the analysis. Also, the accuracy is 100 ± 20%, which
revealed that the method is valid for urine sample analysis. The good reproducibility and
accuracy is not only due to the sample dilution, optimization of MS/MS condition and the
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choosing of good internal standard, but also due to not using other additives in mobile
phase except formic acid and the complete separation of analytes.

Table 2. Linearity and quantificaton limit of metabolites and creatinine in urine
matrix.

Analytes

Linear range
(µM)

Slope

Intercept

(peak area

(peak area

ration/µM)

ratio)

R2

LOQ
(nM)

Creatinine

0.0177-44.0

0.0761

10.6

0.9986

17.7

G3P

0.0029-17.4

0.0211

- 0.107

0.9994

2.91

Kynurenine

0.0048-9.61

0.205

0.523

0.9999

4.81

Proline

0.0026-8.69

0.24

0.814

0.9999

2.61

Sarcosine

0.0056 -56.1

0.0732

0.0942

0.9999

5.62

Uracil

0.0045- 44.6

0.048

0.375

0.9999

4.46

Analyses of Urine Samples
In order to demonstrate the applicability of the developed method, it was applied
to 10 urine sample analyses collected from 5 healthy persons and 5 cancer patients. The
average metabolites levels excreted in urine samples from them were shown in Table 4.
The levels of the urinary metabolites were calculated by using matrix-based calibration
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curves, and then were transformed into nM metabolites/µM creatinine. Creatinine has
been used in many clinical studies as internal standard since its concentration strictly
corresponds to urine dilution. Normally, the urinary excretion from human beings is little
affected by diet, and when normalized to urinary creatinine, the daily excretion rate is
remarkably constant in an individual 57, 68. More urine samples are currently being
analyzed by using this newly developed HPLC-MS/MS method for prostate cancer
biomarker identification and confirmation by measuring these metabolites.

Table 3. Reproducibility and Recovery for metabolites and creatinine in urine
matrix
Low conc.
Analytes

Middle conc.

High conc.

RSD

Recovery

RSD

Recovery

RSD

Recovery

(%)

(%)

(%)

(%)

(%)

(%)

Creatinine

20.1

129

15.3

92.4

8.7

93.5

G3P

13.2

117

9.1

85.1

10.3

91.7

Kynurenine

7.27

111

3.56

96.4

6.57

107

Proline

7.11

112

6.95

95.3

13.2

101

Sarcosine

5.89

90

6.31

92.8

7.85

96.1

Uracil

10.6

108

7.98

96.6

12.3

95
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Table 4. Average metabolites levels excreted in urine samples from five normal
subjects and five cancer-carrying patients (nM metabolites /µM creatinine)

Metabolites

Normal subject mean Cancer patient mean
± SD

± SD

Glycerol-3-phosphate

28.7 ± 0.97

86.6 ± 1.78

Kynurenine

4.16 ± 0.35

7.68 ± 1.13

Proline

2.64 ± 0.02

35.0 ±1.31

Sarcosine

27.1 ± 1.08

118 ± 2.43

Uracil

2.78 ± 0.21

5.3 ± 1.14

CONCLUSION

A simple but powerful HPLC-MS-MS method was developed for simultaneous
separation and quantification of 6 molecules (sarcosine, proline, kynurenine, uracil,
glycerol-3-phosphate and creatinine) in urine samples for the first time. Without using
other additives except formic acid, the six compounds were completely separated on
phenyl-hexyl column within 10 min. The thorough separation directly resulted in good
mass quantification. The factors that affect separation efficiency and quantification
quality have been systematically investigated and optimized. This method is being used
for urinary metabolites determination for early cancer screening in which these five
metabolites are used as biomarkers. Simplicity of sample preparation, fast and complete
separation, super specificity and sensitivity of LC-MS/MS and simultaneous analysis of
these molecules in urine samples by LC-MS/MS in positive mode is certainly useful for
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diagnosis and therapy assessment of prostate cancer. The developed method is promising
and can also be used to detect the six metabolites in other biological matrix, such as
blood.
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ABSTRACT

Polyamines such as spermidine (SPD), spermine (SPM), cadaverine (CAD) and
putrescine (PUT) are small, polycationic molecules that are required for optimal growth
in all cells. In order to detect cell extracts polyamines accurately, a sensitive CE-LIF
method was validated and successfully applied to determine biogenic PAs in bacterial
cell extracts. FITC was used for the off-line derivatization and the FITC-PAs were
separated in less than 8 min at a voltage of 20 kV. This CE-LIF method was proved to be
sensitive, simple, fast, low cost and environment friendly and suitable to detect PAs in
biological samples. Intracellular concentrations of polyamine molecules are maintained
by de noyo synthesis and transport pathways. The human pathogen possesses a putative
polyamine transporter (pot) operon D (potD). Through the measurement of polyamine
intracellular concentrations, the data suggested that potD is involved in polyamine
transport and is important for pathogenesis within various infection models. Polyamine
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transport was associated with the ability of a human pathogen to cause disease for the
first time in this study.

KEYWORDS

Capillary electrophoresis; polyamines; laser-induced fluorescence; cell extract

INTRODUCTION

Polyamines (PAs) such as spermidine (SPD), spermine (SPM), cadaverine (CAD)
and putrescine (PUT) (as shown in Figure 1) comprise a group of ubiquitous aliphatic,
polycationic molecules which are found in central neurons system92, tissue cells93, 94 and
body fluids including serum95 and urine96. They play an important role in cell‘s function
and growth, DNA replication, protein and nucleic acids synthesis, and gene expression9799

. Intracellular polyamines are derived from both de novo synthesis from amino acids

and intracellular uptake from the environment. The intracellular levels of polyamines are
tightly regulated by multiple mechanisms involving both biosynthesis and transport
processes. Although polyamines have been shown to have multiple effects on protein
synthesis and cell proliferation for all cell types, polyamine uptake and synthesis in
pathogenic bacteria has not been well studied. Also, several scientists reported that PA
concentrations in the urine of some tumor patients were higher than those of normal
people100, 101. Despite of the limitations of PAs as biomarker for malignant tumors, PAs
are now still considered as one group of the tumor markers in humans (although not as a
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sole marker). Therefore, the ability to detect PAs concentrations in all type of cells would
be of clinical significance in both pathogenesis studies and early cancer screening.
Methods for separation and determination of PAs have been established by using
gas chromatography (GC) 102,103, high-performance liquid chromatography (HPLC)104-106,
and capillary electrophoresis (CE)107-109 with UV detection. Since PAs do not absorb at
the UV/Vis range, they were detected either by indirect detection or through
derivatization110, 111. These studies used 4-(1-pyrene) butyric acid N-hydroxysuccinimide
ester (PSE), dansyl chloride, and other derivatization reagents to derivatize PAs before
separation by HPLC or CE. However, the detection sensitivity cannot meet the
requirement of some analysis due to the variety of biological samples. In our laboratory,
one PAs quantification method, capillary electrophoresis coupled with laser induced
fluorescence (CE-LIF), was developed by labeling PAs with fluorescein-5-isothiocyanate
(FITC) and then detected by LIF in order to improve detection sensitivity. Also, the
developed method can separate and detect all PAs and catecholamines (CAs)
simultaneously with high sensitivity, which is very crucial in understanding the
mechanism of tumor cells‘ malignancy, early cancer detection, and follow-up after
anticancer drug treatment. In this work, we have applied for the first time the CE-LIF
method to separate and quantify PAs in bacteria cell extracts and associated the
polyamine transport with the ability of a human pathogen to cause disease.
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Figure 1. Structures of 4 polyamines

EXPERIMENTS
Chemicals
All chemicals were of analytical reagent grade unless stated otherwise and used
without further purification. CAD, PUT, SPD, SPM were purchased from Sigma (St.
Louis, MO, USA).
A 0.1 mmol/L stock solution of each PA was prepared in 0.01 mol/L cold
perchloric acid and stored at 4 ºC before use. FITC isomer I was purchased from
Molecular Probes (Eugene, OR, USA). A 0.45 mmol/L of FITC stock solution was
prepared with acetonitrile containing 0.8% (v/v) methanol and 0.5% (v/v) pyridine. A 45
µmol/L of FITC working solution was prepared from the above stock solution with
further dilution by using the same acetonitrile mixture solution. A 0.05 mol/L Na2HPO4
derivatization buffer solution was prepared by dissolution of 7.80 g/L of Na2HPO4 in
deionized water, adjusted to pH 10.95 with 1.0 mol/L NaOH. A 40 mmol/L sodium
tetraborate and 60 mmol/L boric acid mixture buffer solution was adjusted to pH 9.0 with
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1.0 mol/L NaOH and was used as the background electrolyte (BGE). The working
solutions of PA standards were diluted with this BGE solution. Deionized water (18.2
MO) was obtained from a Milli-Q system (Millipore, Bedford, MA, USA).

Sample Extraction
The pellets were washed three times with 15 mL 0.3 mol/L sucrose (pH 7.40)
under 1400 rpm for 5min. A 500-600 L aliquot of 15% iced trichloroacetic acid (TCA)
was added to the cell pellets. The samples were stored at 4 ºC for 2 h. PAs and CAs that
were complexed to DNA/RNA, proteins, and phospholipids were released under these
treatment conditions. Proteins and other macromolecule precipitates were removed by
centrifugation at 10,000×g for 15 min at 4 ºC. The TCA-soluble fraction was extracted
six times with 6 times with 1.5mL diethyl ether to remove TCA. Then the solution was
set to 1.0 mL. After the pH was increased to 1-2 through ether extraction, the sample
extract were then used for derivatization to determine total PAs.

Derivatization Procedure
10 µL PAs working solution or extracts was mixed with 10 µL of 45 µmol/L
FITC, 200 µL of 0.05 mol/L Na2HPO4 buffer, and vortexed and reacted in the dark at 25
ºC for 6 hrs 40min. The solution was then diluted twice with H2O before injection to the
CE system. A blank solution was prepared at the same time to serve as a control.

Instrumentation
A Beckman P/ACE MDQ CE system with an LIF detector was used for all
electrophoretic separations. Excitation was at 488 nm (argon ion laser) and the emission
intensity was monitored at 520 nm (band-pass filter, bandwidth 10 nm). A 50 µm ID
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fused-silica capillary from Polymicro Technologies (Phoenix, AZ, USA) of 58 cm length
(48 cm from inlet to the detector window) was used and themostated at 25 ºC. The
capillary was first conditioned with 1.0 mol/L HCl, 1.0 mol/L NaOH and methanol for 2
min each as described in the P/ACE MDQ CE instrumental manual. Then the capillary
was rinsed with deionized water for 2 min at a pressure of 60 psi and equilibrated with
BGE buffer before sample analysis. Samples were injected by pressure at 0.5 psi for 15 s,
and separations were performed under 20 kV for 15 min with a positive high voltage. The
data were collected and processed by Beckman P/A CE 32 Karat software Version 4.0.
The capillary was rinsed 2 min with 0.1 mol/L NaOH, water, and BGE after each run.

RESULTS AND DISCUSSION

A representative electropherogram of FITC-PA derivatives and unreacted labeling
agent is shown in Figure 2, demonstrating the excellent separation of these analytes under
the optimized conditions. Four PAs, which exist in biological cell extracts and are of
interest to biological researchers, were completely separated in less than 8 min. The
migration order was SPM, SPD, CAD, PUT, and FITC. This elution order can be
explained on the basis of the molecular structure and mass-to-charge ratio. Because the
negative charges on FITC-PAs are from FITC, the high mass-to-charge ratio results in a
higher mobility. Due to the similar mobility of FITC-PAs, they moved in very short
migration times to the detector side.
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Figure 2. Electropherogram of standard mixtures of FITC-PAs under optimal
derivatization and separation conditions with LIF detection. Capillary: 50 µm ID × 58 cm
length (48 cm from inlet to the detector window); Temperature: 25 ºC; Sample injection:
0.5 psi for 15 s; Separation voltage: 20 kV; Separation time: 15 min; Detector: 488nm
(excitation) and 520 nm (emission); BGE: 40 mmol/L sodium tetraborate and 60 mmol/L
boric acid mixture buffer solution, pH = 9.0.

Linearity, Reproducibility, Detection Limits and Recovery Study
The linearity, reproducibility, detection limits, and recoveries for determination of
FITC-PA derivatives were completely studied and are listed in Table 1. The
reproducibility was expressed as relative standard deviation (RSD) values for both
migration time and peak area and was calculated by using 0.50 mmol/L of PA standard
solutions (n = 5). The RSD values of migration time were between 0.98% and 2.76% and
the RSD for peak areas were between 1.86% and 3.15%, which means this technique is
reproducible. The linearity of the method was determined by using standard mixtures at
six concentrations from 0.05 to 1.0 mmol/L, correlation coefficients ranged from 0.9568
to 0.9975, and detection limits varied from 1.97 and 2.98 nmol/L with a signalto- noise
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ratio (S/N) of 3, which is sensitive enough for PA analysis in cell extracts. The recoveries
are between 87.4 and 92.5, which indicate that the method is reliable.

Table 1. The linearity, reproducibility and detection limits of FITC-PA derivatives
by CE-LIF. Derivatization and separation conditions are the same as that in Figure 2.
RSD (%)
PA Standards

Linearity
2
(R )

Detection Limit
(nM, S/N=3)

Recovery (%)
± SD

Migration
Time

Peak
Area

Spermidine

1.86

2.17

0.9896

2.05

90.1 ± 1.24

Putrescine

0.98

1.86

0.9975

1.97

92.5 ± 2.98

Spermine

2.14

3.12

0.9682

2.98

87.4 ± 1.65

Cadaverine

2.76

3.15

0.9568

2.76

88.7 ± 2.31

Analysis of polyamines in bacterial cell extracts.
Bacterial cell samples were analyzed (n = 5) using the optimized CE-LIF method.
PA peaks in the cell extracts were identified by retention time and standard addition. The
results obtained from the analysis of bacterial cell extracts are shown in Table 2.
Polyamines have been shown to be involved in various steps of cell growth. Both
WU2 and WU2∆potD were able to grow in the presence of methylglyoxal
bis(guanylhydrazone) (MGBG) and α-difluoromethylornithine (DFMO), although
WU2∆potD grew much more slowly, possessing an extended lag phase compared with
WU2 results. To determine whether the final intracellular polyamine concentrations for
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Table 2. Concentration of intracellular polyamines for strains WU2 and WU2∆potD

Growth Medium and Strain

Concentration (µM)
Spermidine

Cadaverine

Putrescine

WU2

25.56 ± 0.64

0.289 ± 0.048

0.479 ± 0.04

WU2∆potD

21.64 ± 0.455

3.194 ± 0.375

3.555 ± 0.351

WU2

102.61 ± 3.08

3.897 ± 0.329

7.161 ± 0.237

WU2∆potD

22.64 ± 1.025

2.181 ± 0.195

3.37 ± 0.201

WU2

18.935 ± 1.35

0.668 ± 0.119

1.44 ± 0.084

WU2∆potD

21.875 ± 0.76

0.342 ± 0.02

0.519 ± 0.048

WU2

59.27 ± 5.185

1.127 ± 0.412

1.199 ± 0.042

WU2∆potD

7.075 ± 0.48

0.116 ± 0.013

0.115 ± 0.023

THY

THY+ inhibitors

CDM + choline

CDM + choline +inhibitors

Note: potD – polyamine transporter D; WU2- mouse-virulent serotype 3 strain;
WU2∆potD – potD deficient mutant; THY – Todd-Hewitt yeast extract; CDMchemically defined medium.

both WU2∆potD and WU2 were similar, the concentration of intracellular polyamines
was compared for both WU2 and WU2∆potD. In Table 2, the intracellular concentrations
of the polyamines cadaverine, spermidine, and putrescine are compared for WU2 and
WU2∆potD grown in THY or CDM plus 1 mg/ml choline with or without MGBG and
DFMO added to the medium. The intracellular levels of the all three polyamines for
WU2∆potD grown in both THY and CDM plus 1 mg/ml choline were similar, and these
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concentrations did not differ much after the addition of MGBG and DFMO. For WU2,
the intracellular levels of spermidine and putrescine did not differ much for both THY
and CDM plus 1 mg/ml choline with or without MGBG and DFMO. Interestingly, the
addition of MGBG and DFMO to the both mediums did increase the intracellular
concentrations of cadaverine within WU2 fivefold for cells grown in THY and threefold
for cells grown in CDM plus choline. Alternative polyamine transport systems have been
previously reported for E. coli. The unaffected growth kinetics along with the increased
levels of intracellular cadaverine within WU2 in the presence of MGBG and DMFO
supported the idea of the existence of alternative polyamine transport systems in the
pneumococcal as well.

CONCLUSION

A sensitive CE-LIF method was successfully validated and applied to determine
biogenic PAs in bacterial cell extracts. FITC was used for the off-line derivatization and
the FITC-PAs were completely separated in less than 8 min at a voltage of 20 kV. This
CE-LIF method was proved to be sensitive, simple, fast, low cost and environment
friendly and suitable to detect PAs in biological samples. By quantifying PAs in bacterial
cell extracts, potD was proved to be involved in polyamine transport and is important for
pathogenesis within various infection models. Polyamine transport was associated with
the ability of a human pathogen to cause disease for the first time.
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ABSTRACT

Coenzyme A (CoA) is a group of active metabolic compounds that facilitate over
100 chemical reactions in animal and plant cells. It mainly serves as an acyl carrier in
many metabolic reactions and initiates the trcarboxylic acid cycle that produces more
than 90% of the energy required for life processes. Measurements of short-chain and
long-chain CoA compounds in a variety of tissues by using HPLC and CE-UV detection
have been reported, but these techniques do not allow one to simultaneously determine all
the possible coexisting CoA‘s and their derivatives in plant tissues with sufficient
sensitivity. In this paper, a method of quantitative determination of 5 short-chain CoA‘s
in plant tissues by using capillary electrophoresis with laser-induced fluorescence
detection (CE-LIF) was developed. Under optimized derivatization and electrophoresis
conditions, different CoA‘s that were derivatized with FITC were separated and
quantified at the pmole level. A fused silica capillary with a 75 m (i.d.)

57 cm was

used for the separation and 150 mM borate buffer (pH 9.00) was used as a background
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electrolyte. The separation was carried out at 25 kV and completed in less than 13 min.
The effects of derivatization time, buffer concentrations, and pH value on derivatization
efficiency were also investigated systematically. This newly developed can be used to
detect CoA‘s in both plant and animal tissues.

KEYWORDS

Coenzyme A; capillary electrophoresis; laser-induced fluorescence; plant tissue

INTRODUCTION

Coenzyme A (CoA) is one of the most active metabolic compounds. It facilitates
more than 100 chemical reactions in cells, including the metabolism of amino acids,
carbohydrates, and lipids112-114. Most importantly, CoA initiates the tricarboxylic acid
(TCA) cycle that produces more than 90% of the energy required for life processes 115.
CoA serves primarily as an acyl carrier in many metabolic reactions due to its active thiol
(SH) group, which covalently bonds to an acyl group to form thioesters 116, 117. The acyl
group can then be actively transferred to various acceptor molecules due to its high free
energy released during hydrolysis, as in the case of fatty acid biosynthesis. The chemical
structure of CoA, and the different portions of the molecule are illustrated in Figure 1.
Research data have also shown that CoA and its derivatives have a site-specific and
reversible interaction with certain enzyme systems 118 and can act well below the critical
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micelle level119. They are considered to be important effectors in cell metabolism because
of this unique function. Despite the importance of this molecule in many crucial
reactions, it accumulates at low concentration in cells. In fact its low abundance has been
a major hindrance in elucidating the metabolism of this molecule and elucidating
metabolic processes in which it is required as a cofactor. To discover the detailed
functions of CoA and its derivatives in tissues and subcellular organelles, it is critical to
develop an efficient, simple, and sensitive method to detect CoA compounds in biological
samples.
Different methods have been reported for determining short-chain and long-chain
CoA compounds in a variety of tissues, including enzymatic assays120, 121, highperformance liquid chromatography (HPLC) conjugated with either spectroscopic or
fluorometric detection and capillary electrophoresis with UV detection122, 123. Since
enzymatic assays only allow the determination of one CoA compound at a time, they are
not useful for simultaneous determination of all possible coexisting CoA's and their
derivatives. Although the HPLC method has long been used as the main technique for
measurement of acyl CoA esters, it has quite a few drawbacks, including (1) long running
times (45-120 min) associated with generating a large amount of organic wastes, (2)
inadequate separation of unknown compounds with short-chain CoA's leading to
misidentification and inaccurate quantitation, (3) large shifts of baseline during gradient
elution programming, which often requires further solvent purification, and (4) tedious
procedures for sample preparation and sample analysis. High-performance capillary
electrophoresis (HPCE) has proven to be a rapid, simple, and sensitive technique for
separating charged biomolecules with very high resolution124-127. However, the current

63
method using UV as detector128 has the low sensitivity problem and cannot meet the
requirement of CoA measurement in some biological samples. In this paper, we have
demonstrated a capillary electrophoresis-laser induced fluorescence (CE-LIF) method for
the first time to separate and quantify CoA compounds in plant leaves. CoA compounds
first were derivatized with fluorescein-5-isothiocyanate (FITC), separated by CE and then
detected using by LIF in order to improve detection sensitivity. This fast, sensitive and
reliable method can be applied to determine CoA‘s in both plant and animal tissues.

Figure 1. Chemical structure of Coenzyme A

MATERIALS AND METHODS

Chemicals
CoA standards were purchased from Sigma-Aldrich (St. Louis, MO, USA). FITC
was obtained from Invitrogen (Carlsbad, CA, USA). All other chemicals that were used
for buffer preparation and capillary rinsing, such as borate, acetone, methanol, sodium
hydroxide and hydrochloric acid, were also from Sigma-Aldrich (St. Louis, MO, USA)
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and of analytical reagent grade unless stated otherwise. Deionized water (18.2 MΩ) from
Millipore Simplicity 185 - system (Millipore, MA, USA) was used to prepare standard
solutions, BGE and other solutions.

Preparation of BGE
The derivertization buffer and BGE solution containing 170 mM and 150 mM
borate respectively were prepared with deionized water and the pHs were adjusted to 9.00
by adding 1.0 M NaOH in the buffer before diluting it to the final volumes. These
solutions were filtered through the 0.45µm membrane filter before use.

Preparation of Standard CoA Solutions
The 1.0 mM of CoAs and FITC stock solutions were prepared in DI water and
acetone respectively. All stock solutions were kept at −20oC. The working solutions were
prepared by diluting the stock solutions to the desire concentrations.

Sample Extraction
Plant leaves were harvested, immediately frozen in liquid N2 and stored at –80°C
until used. Before analysis, the frozen leaves (0.5–1.0 g fresh weight) was powdered
using mortar and pestle, and then the powder was suspended in 2.0 mL of 5 % (w/v) iced
trichloroacetic acid (TCA). The TCA suspensions were vortexed, centrifuged, and the
supernatant was recovered. Repeated partitioning against diethyl ether removed TCA
from the extracts, which were then dried under vacuum. The residues were dissolved in
DI H2O and ready for derivatization.
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Derivatization Procedure
12 µL CoA working solution or extracts was mixed with 30 µL of 1.0 mmol/L
FITC, 258 µL of 0.2 mol/L borate buffer, vortexed and then reacted in the dark at 40 C in
dry incubator for 10hrs. The solution was then diluted twice with H2O before injection to
the CE system. A blank solution was prepared at the same time to serve as a control.

Instrumentation
All CE experiments were carried out on a Beckman Coulter P/ACE MDQ
instrument (Beckman Instruments, Fullerton, CA, USA) equipped with a LIF detector.
Excitation was at 488 nm (argon ion laser) and the emission intensity was monitored at
520 nm (band-pass filter, bandwidth 10 nm). Electrophoretic data were acquired and
analyzed by 32 Karat software versions 4. Separations were performed in fused silica
capillaries (Polymicro Technologies, Phoenix, AZ) with 75µm (i.d.) × 57cm (effective
length). New capillaries were conditioned by rinsing with methanol for 15 min, deionized
water for 5 min, 1.0 M HCl for 5 min, followed by deionized water for 5 min again, then
1.0 M NaOH for 20 min and deionized water for 5 min. The capillary was rinsed with
deionized water for 5 min and then pre-run with BGE for 20 min under 25 kV every
morning to obtain the best reproducibility. Samples were injected into the capillary at 0.5
psi for 10 s. After each analysis, the capillary was rinsed successively with 0.1 M NaOH
for 1.0 min, deionized water, and BGE for 2.0 min respectively. CoA separation was
carried out at 25 kV under 25 ºC.
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RESULTS AND DISCUSSION

CoAs are suitable to conjugate with fluorescence agent FITC and then be
analyzed by capillary electrophoresis, due to the amine group in the molecule, the
charges they carry, diverse molecular weight, and hydrophilic property of the derivatives.
The quality of the CoA measurement in tissue depends on a number of derivatization and
analytical parameters, such as derivatization and running buffer composition, pH, and
concentration, the applied voltage on CE, the length and diameter of the capillary, and the
sample size introduced, and so on. All these conditions were investigated systematically
in this study in order to get the optimum derivatization and separation conditions. Figure
2 showed the separation of 5 CoA standards under optimal conditions by using CE-LIF.
The derivatization was conducted in a 170 mM borate buffer at pH=9.00 under 40 C for
10hrs in dark. The running buffer was composed of 150 mM borate (pH=9.00) and the
separation was conducted at 25 kV under with LIF detector 25 ºC.

Optimization of Derivatization
FITC has been widely used in the derivatization of amines in CE 109, 129, because it
can react with primary and second amines and forms a derivative with an excitation
maximum at 488 nm, which is coincident with the argon laser, and an emission maximum
at 516 nm. The product information recommended condition for FITC derivatizationis is
0.2 mol/L carbonate buffer. In order to use the same buffer in derivatization and
separation, and at the same time avoid the bubble problem of carbonate at the same time,
borate was used as derivatization buffer. Eight different borate concentrations (30, 50,
100, 150, 170, 200, 250 and 300 mM) were examined to compare the derivatization
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efficiency, which is shown in Figure 3. With the increase of the borate concentration, the
peaks got more and more intensive until it reached 170 mM. Above 170 mM, no apparent
derivatization efficiency improvement was observed with the increasing of derivatization
buffer concentration. Since more concentrated buffer will adversely affect stability of
derivatives109, we chose 170 mM as the derivatization buffer concentration, even though
high concentration buffer is of benefit to the derivatization.

Figure 2. Electropherogram of the separation of 5 CoA standards under optimal
conditions by using CE-LIF. The derivatization was conducted in a 170 mM borate buffer
at pH=9.00 under 40 C for 10hrs in dark. The running buffer was composed of 150 mM
borate (pH=9.00) and the separation voltage was 25 kV with LIF detector. The separation
was finished in a capillary with 75µm (i.d.) × 57cm (effective length) at 25°C. Sample
was injected under 0.5psi for 10s. Peak identification: 1, Isovaleryl coenzyme A; 2,
Acetyl coenzyme A; 3, n-Propionyl coenzyme A; 4, Isobutyryl coenzyme A; 5, Malonyl
coenzyme A.
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The most crucial parameter for the amine derivatization using FITC is the buffer
pH. Slightly basic buffer would be beneficial for derivatization109, since the derivatization
involves the deprotonation of the amino-group, and basic solution will help shifting the
dissociation equilibration to the deprotonation and therefore improve the derivatization
efficiency. Buffer pH effects on derivatization efficiency of five CoAs were investigated
and the results were shown in Figure 4. The results in figure 4 demonstrated that the
derivatizing pH had remarkably effects on the derivatization efficiency and the efficiency
increased continuously as pH increased until about pH 9.0, at which the fluorescence
response achieved the highest value. Afterwards, the reaction efficiency decreased as the
pH went up. Therefore, an optimized pH for derivatization in this study was maintained
at 9.0 for the highest reaction efficiency. The pH of the derivatization buffer not only
affected derivatization efficiency, but also affected separation result of capillary
electrophoresis. A good separation will be obtained when the pH of derivatization buffer
is the same as that of the running buffer109. When the pH of derivatization buffer is lower
than that of the running buffer, the acidity of sample band will result in the adsorption of
FITC on the capillary wall and the tailing system peak will interfere with sample peaks.
Therefore, the pH of the derivatization buffer was the same as that of the running buffer
in this study, which will be discussed later.

69

Figure 3. Effect of derivatizaion buffer concentration on the separation of 5 CoA
standards. The experimental conditions were the same as those of Figure 2, except for
the borate concentrations.

Figure 4. The derivatizaion pH effect on the separation of 5 CoA standards. The
experimental conditions were the same as those of Figure 2, except for the pHs of the
derivatizaion buffer.
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FITC to CoA ratio was also studied by using n-Propionyl CoA (due to the
structural similarity of CoAs) and the result was shown in Figure 5. The efficiency of the
derivatization reaction increased with the increasing of the FITC to CoA ratio. However,
too much FITC will introduce interference and result in poor separation and
quantification. For optimal detection sensitivity and accuracy, a FITC to CoA ratio of 5
was adopted in this study.

Figure 5. FITC to CoA ratio on the separation of 5 CoA standards. The experimental
conditions were the same as those of Figure 2, except for the FITC to CoA ratio. Peak
identifications were the same as those in Figure 2.

The temperature and time of derivatization reaction were also found to affect the
derivatization efficiency. After a series of experiments (data was not shown), 40ºC was
considered the best temperature, since the relatively higher temperature speeded up the
reaction; but higher than 40ºC, the derivatization product will decompose. The systematic
study of the derivatization time effect on derivatization efficiency is shown in Figure 6.
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We chose 10 hrs as derivatization time prior to injection to CE for analysis. Longer
reaction time may induce product decomposition.

Figure 6. The derivatizaion time effect on the separation of 5 CoA standards. The
experimental conditions were the same as those of Figure 2, except for the time of the
derivatizaion. Peak identifications were the same as those in Figure 2.

Optimization of Separation
Running buffer is the key media for CE separation and so optimization running
buffer is very important. Good buffer should have the following characteristics: good
resolution; low current, low Joule heat; high fluorescence quantum yield and good buffer
pH range and capacity. In this study, borate solution has been chosen as the running
buffer, because of its buffer pH range, low current conductivity and good pH range for
FITC derivatives. As mentioned above, the derivatization reaction was conducted in the
alkaline solution. The running buffer pH should be basic in order to get good separation
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and sensitivity. The pH of the running buffer will influence the fluorescence intensities of
FITC derivatives. According to the FITC product information130, the fluorescence
intensities are low and steady when pH is below 3.0. With the increasing of pH from 3.0
to 6.0, the fluorescence intensities rapidly increase. When pH is higher than 6.0, the
fluorescence intensities reaches to a maximum and become steady. Therefore, good
detection sensitivity and signal stability can be obtained under a basic condition; For the
current study, four pHs (8.50, 9.00, 9.50 and 10.00) were tested and the result is shown in
Figure 7. The optimal sensitivity and separation was obtained under pH 9.00. Separation
efficiency was also greatly affected by the BGE concentration. Since FITC derivatized
products were negatively charged and migrated against the EOF, a low molar
concentration of BGE buffer, which decreased the EOF, decreased the separation
efficiency. On the other hand, when the BGE concentration was too high, the EOF and
Joule heating greatly increased, therefore causing a decrease in separation efficiency.
Based on the above consideration, 150 mM borate was used.
The effect of applied voltages on the separation of five analytes was also
investigated (data not shown). It was found that with the increases of the applied voltage,
the analytes migration times were decreased and fast separation was obtained. However,
when the applied voltage was higher than 25 kV, the analyte peaks were too close and it
is hard to observe a baseline separation. In addition, due to the Joule heat caused by the
increased electrophoretic current, the peak width expanded, which reduced the separation
efficiency. Therefore, 25 kV was selected as the optimized applied voltage in our study.
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Figure 7. The pH effect on the separation of 5 CoA standards. The experimental
conditions were the same as those of Figure 2, except for the pHs of the running buffer.
Peak identifications were the same as those in Figure 2.

Linearity, Detection Limits, and Reproducibility
A representative electropherogram of FITC-CoA derivatives and unreacted
labeling agents is shown in Figure 2, demonstrating the excellent separation of these
analytes under the optimized conditions. Five CoAs, which commonly exist in biological
extracts and are of interest to biological researchers, were completely separated in less
than 13 min. The migration order was 11, FITC, 1, 9, 8, 3. This elution order can be
explained on the basis of the molecular structure and mass-to-charge ratio. For all 5
FITC-CoAs, the mass-to-charge ratio is high and a higher mobility is expected.
Therefore, they moved in very short migration times to the detector side.
The linearity, reproducibility and detection limits for determination of FITC- CoA
derivatives are listed in Table 1. The reproducibility was expressed as relative standard
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deviation (RSD) values for both migration time and peak area and was calculated by
using 0.1 mmol/L CoA standard solutions (n = 5). The RSD values of migration time
were between 1.97% and 3.89% and the RSD for peak areas were between 2.86% and
5.46%, which indicates a good reproducibility. The linearity of the method was
determined by using standard mixtures at six concentrations from 0.5 to 500 nmol/L and
correlation coefficients ranged from 0.9932 to 0.9988. Detection limits varied from 0.32
and 1.87 nmol/L with a signal to- noise ratio (S/N) of 3, which is sensitive enough to
detect tissue extract CoA‘s.

Table 1. The linearity, reproducibility and detection limits of FITC- CoA derivatives by
CE-LIF. Derivatization and separation conditions are the same as that in Figure 2.
RSD (%)
CoA Standards

Linearity
2
(R )

Detection Limit
(nM, S/N=3)

Migration
Time

Peak
Area

Acetyl coenzyme A

2.27

3.38

0.9986

1.19

Malonyl coenzyme A

1.97

2.86

0.9972

0.26

Isobutyryl coenzyme A

2.06

3.05

0.9988

1.37

n-Propionyl
coenzyme A

2.13

3.32

0.9968

0.12

Isovaleryl coenzyme A

3.89

5.46

0.9932

0.61
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Analysis of Coenzyme A’s in Plant Leave Cell Extracts
Plant leaves were analyzed (n = 5) using the optimized CE-LIF method. CoA
peaks in the cell extracts were identified by retention time and standard addition. The
extraction recoveries for CoA‘s present in leave extracts and results obtained from the
analysis of cell extracts are shown in Table 2. The results were comparable to those of
HPLC methods for CoA‘s in plant tissue131.

Table 2. CE-LIF results of Coenzyme A levels in plant tissue. The experimental
conditions were the same as those of Figure 2. Amounts reported here were expressed as
the mean ± standard deviation for three measurements.

CoA‘s

Concentration
(nmol/g fresh weight)

Recovery (%)
± SD

Acetyl coenzyme A

5.19 ± 0.2

87.6 ± 1.64

Malonyl coenzyme A

0.96 ± 0.1

83.5 ± 2.21

Isobutyryl coenzyme A

3.55 ± 0.05

90.8 ± 3.22

n-Propionyl coenzyme A

0.92 ± 0.01

88.7 ± 1.58

Isovaleryl coenzyme A

2.01 ± 0.05

91.2 ± 3.16

CONCLUSION

A sensitive CE-LIF method was successfully developed for determination of
CoA‘s in plant cell extracts. FITC was used for the off-line derivatization and it was
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found that the derivatization efficiency was the highest in 170 mM borate buffer at pH
9.00. Using 150 mM borate BGE at pH 9.0, FITC-CoA‘s were separated in less than 13
min at a voltage of 25 kV. This CE-LIF method is sensitive, fast, at low cost and
environment friendly. It can be applied to measure CoA‘s in both plant and animal tissue
and has the potential to be used for metabolite study in which CoA is required.
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